Table 2. BCL2 expression for molecular subtypes according to NCCN classification and St. Gallen classifications.
| Characteristic | All No. (%) | BCL2 expression | p-value† | |||
|---|---|---|---|---|---|---|
| No No. (%) |
Yes No. (%) |
p-value* | OS | BCSS | ||
| Total | 9,468 (100.0) | 2,671 (28.2) | 6,797 (71.8) | < 0.001 | < 0.001 | |
| NCCN | < 0.001 | |||||
| HR(+)/HER2(−) | 4,998 (52.8) | 558 (11.2) | 4,440 (88.8) | < 0.001 | < 0.001 | |
| HR(+)/HER2(+) | 899 (9.5) | 212 (23.6) | 687 (76.4) | 0.046 | 0.002 | |
| HR(−)/HER2(+) | 847 (8.9) | 692 (81.7) | 155 (18.3) | 0.256 | 0.436 | |
| HR(−)/HER2(−) | 1,501 (15.9) | 904 (60.2) | 597 (39.8) | 0.104 | < 0.001 | |
| Unknown | 1,223 (12.9) | 305 (24.9) | 918 (75.1) | < 0.001 | < 0.001 | |
| St. Gallen | < 0.001 | |||||
| Luminal A | 2,717 (28.7) | 232 (8.5) | 2,485 (91.5) | < 0.001 | < 0.001 | |
| Luminal B/HER2(-) | 1,762 (18.6) | 273 (15.5) | 1,489 (84.5) | < 0.001 | < 0.001 | |
| Luminal B/HER2(+) | 899 (9.5) | 212 (23.6) | 687 (76.4) | 0.046 | 0.002 | |
| HER2 | 847 (8.9) | 692 (81.7) | 155 (18.3) | 0.256 | 0.436 | |
| TN | 1,501 (15.9) | 904 (60.2) | 597 (39.8) | 0.104 | < 0.001 | |
| Unknown | 1,742 (18.4) | 358 (20.6) | 1,384 (79.4) | < 0.001 | < 0.001 | |
BCL2=B-cell CLL/lymphoma 2; NCCN=National Comprehensive Cancer Network; OS=overall survival; BCSS=breast cancer-specific survival; HR=hormonal receptor; HER2=human epidermal growth factor receptor 2; TN=triple negative.
*Chi-square test; †Log-rank test.